secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001654954-25-003305
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity
--------------------------------------------------------------------------------

- Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.
- Company reported stockholders' equity of $1.6M as of Dec 31, 2024, below required threshold.
- Dermata has 45 days, until May 9, 2025, to submit a plan; possible extension to Sept 21, 2025.
- Securities continue trading on Nasdaq while company evaluates options to regain compliance.
- If plan rejected or compliance not regained, delisting proceedings may commence; hearing available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003305/0001654954-25-003305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003305/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-003305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer